Financial Data and Key Metrics Changes - In Q4 2025, Macy's, Inc. reported net sales of $7.6 billion, exceeding guidance of $7.35-$7.5 billion, compared to $7.8 billion last year [23] - Comparable sales rose 1.8%, significantly above guidance for a decline of 2.5% to flat [24] - Adjusted diluted EPS was $1.67, exceeding the guidance range of $1.35-$1.55 [27] - For the full year 2025, adjusted diluted EPS was $2.32, well above the guidance of $2-$2.20 [10] Business Line Data and Key Metrics Changes - Macy's nameplate achieved 0.6% go-forward comparable sales growth, a 190 basis points improvement year-over-year [10] - Bloomingdale's saw a remarkable 9.9% growth in comparable sales, marking its best holiday result on record [24] - Bluemercury's comparable sales increased by 1.6%, driven by strong performance in dermatological skincare and fragrances [15] Market Data and Key Metrics Changes - Macy's digital channel represents approximately one-third of annual sales, benefiting from a modernized online presence [11] - The company reported a 17.1% increase in credit card revenue, totaling $205 million, driven by a healthy credit portfolio [25] - Macy's Media Network revenue was $72 million, up 12.5% [25] Company Strategy and Development Direction - The "Bold New Chapter" strategy focuses on sustainable profitable growth, with significant progress made in 2025 [7][8] - The company is expanding its Reimagine program to 200 locations, which is expected to drive further growth [17] - Investments in staffing, localized events, and improved assortments are key components of the strategy [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic uncertainties while building on recent momentum [21] - The guidance for 2026 reflects a prudent approach, considering potential macroeconomic and geopolitical factors [36] - The company anticipates net sales of approximately $21.4 billion to $21.65 billion for 2026, with comparable sales expected to range from -0.5% to +0.5% [37] Other Important Information - The company achieved a free cash flow yield of over 15%, with operating cash flow of $1.4 billion for the year [28] - Capital expenditures for 2025 were $740 million, down from $882 million in 2024, reflecting the completion of several long-term projects [30] - The company returned $448 million to shareholders, including $197 million in cash dividends [31] Q&A Session Summary Question: How does Macy's plan to remain resilient amidst consumer volatility? - Management expressed confidence in the growth across all nameplates and the strength of the balance sheet, despite external uncertainties [43][44] Question: What are the expectations for AUR versus units? - Management noted that AUR continues to grow, reflecting improved assortments and a positive consumer response [46] Question: Can you elaborate on Bloomingdale's recent performance? - Management highlighted broad-based growth across various categories and strong vendor support, indicating a positive outlook for Bloomingdale's [51] Question: What actions are being taken to appeal to price-sensitive consumers? - The company maintains a balance of promotional offerings and high-quality brands to cater to different consumer segments [58][60] Question: What are the core operational drivers of gross margin improvement? - Management indicated that improving assortments and enhancing the omni-channel experience are key drivers of gross margin performance [61]

Financial Data and Key Metrics Changes - For the full year 2025, total revenues from selling goods were $51.8 million, a modest decrease compared to 2024, driven by changes in quantities sold to Chiesi's inventory and a change in average net selling price due to increased commercial patients in Europe [8] - The company recorded a net loss of $6.6 million in 2025 compared to a net income of $2.9 million in 2024, reflecting increased investment in the clinical pipeline [10] - As of December 31, 2025, the company held $30.3 million in cash equivalents and short-term bank deposits, with a projected cash balance of approximately $50 million by early April 2026 [10] Business Line Data and Key Metrics Changes - Revenues from Chiesi are projected to be approximately $33 million-$35 million in 2026, representing growth of more than 50% [10] - Revenues from Elelyso are expected to be approximately $20 million-$23 million in 2026 [10] - Revenues from license and R&D services increased to $0.9 million, mainly related to agreements with Chiesi [8] Market Data and Key Metrics Changes - The Fabry market is projected to reach approximately $3.4 billion by 2030, with Elfabrio's differentiated profile enhancing its competitive positioning [6] - The approval of the every four weeks dosing regimen in Europe is expected to significantly enhance Elfabrio's market position [5] Company Strategy and Development Direction - The company aims to execute its strategy comfortably, including clinical trials, supported by a strong cash position and projected revenue growth [4][12] - The company is advancing its pipeline with PRX-115 for uncontrolled gout and PRX-119 for renal conditions, targeting high unmet needs [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the Fabry market and the potential for Elfabrio to capture a significant market share [5][12] - The company anticipates a productive 2026, driven by a growing number of patients on Elfabrio and a strong financial position [12] Other Important Information - The European Commission approved the 2 mg/kg every four weeks dosing regimen for Elfabrio, which is expected to enhance long-term management for patients with Fabry disease [3][4] - The company expects to continue increasing R&D investment as its clinical programs advance [9] Q&A Session Summary Question: Insights on marketing initiatives for Elfabrio in the U.S. and the impact of the new dosing regimen in Europe - Management highlighted that Chiesi is implementing various promotional activities to increase patient numbers and that the new dosing regimen provides a competitive edge [15][17] Question: Positioning of PRX-115 in the gout market - Management discussed the potential competitive advantages of PRX-115, including improved dosing frequency and safety, and projected a significant market opportunity for uncontrolled gout [18][22] Question: Target indications for PRX-119 and potential commercial opportunities - Management indicated that they are targeting high unmet need renal conditions and will provide updates on specific indications in the future [23][24] Question: Timeline for rollout of the four-week dosing regimen for Elfabrio in Europe - Management stated that the rollout will vary by country, with expectations for effects to start in the second half of 2026 [27][31]

Financial Data and Key Metrics Changes - In 2025, XOMA Royalty reported total GAAP income and revenue of $52.1 million, a significant increase from $28.5 million in 2024 [21] - Total cash receipts grew by 9% to $50.5 million, with royalty receipts reaching approximately $34 million, marking a 68% increase compared to 2024 [21] - Full-year GAAP net income was $31.7 million, compared to a GAAP net loss of $13.8 million in 2024 [23] Business Line Data and Key Metrics Changes - The company added 22 assets to its portfolio in 2025, including 7 commercially available programs, enhancing its recurring revenue sources [4][5] - The growth in royalty receipts was driven by VABYSMO and OJEMDA, along with contributions from MIPLYFFA following its approval [21] - Six programs achieved clinical, regulatory, and business development events, leading to approximately $17 million in cash milestone payments [21] Market Data and Key Metrics Changes - The company is seeing promising launches from several commercial-stage programs, with potential geographic expansions anticipated [6] - The portfolio includes 14 programs in registrational stage, indicating multiple catalysts for potential top-line royalty growth in the coming years [8] Company Strategy and Development Direction - XOMA Royalty aims to build a diversified portfolio of biotechnology royalty and milestone assets while maintaining disciplined capital allocation [11] - The company executed a strategic revenue share transaction with Takeda, adding potential royalty and milestone payments across 9 programs [10] - The focus remains on innovative transactions and underappreciated opportunities to expand the portfolio without diluting shareholder value [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for royalty receipts, particularly from VABYSMO, OJEMDA, and MIPLYFFA [32] - The company is approaching an inflection point where royalty receipts alone could cover operating expenses by 2027 [28] - Management remains optimistic about the potential for future cash flow growth from the expanding portfolio and ongoing clinical developments [29] Other Important Information - The unrestricted cash position increased to over $80 million, providing ample resources for future investments [12] - The company maintained a flat share count compared to 2023, avoiding shareholder dilution while achieving positive operating cash flows [13] Q&A Session Summary Question: Growth prospects for royalty receipts on approved products - Management indicated strong growth prospects, particularly from VABYSMO, with double-digit growth and positive expectations for OJEMDA and MIPLYFFA [32] Question: Confidence in Tremfya economic opportunity - Management expressed confidence in the breach claim related to Tremfya, citing historical relationships and potential royalty rates [34] Question: Prioritization of capital deployment between share buybacks and new deals - Management emphasized a balance between returning capital to shareholders and investing in new opportunities, favoring internal investments to enhance cash flow per share [45] Question: Size of the opportunity for Rezolute's program for ersodetug - Management estimated the combined market opportunity for the two indications to be around $1 billion, with a favorable split between congenital and tumor hyperinsulinism [48]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was CNY 194.4 billion, up 13% year-on-year [36] - Gross profit increased to CNY 108.3 billion, reflecting a 19% year-on-year growth [36] - Non-IFRS operating profit was CNY 69.5 billion, up 17% year-on-year [37] - Non-IFRS net profit attributable to equity holders was CNY 64.7 billion, also up 17% year-on-year [37] - Overall gross margin improved to 56%, up 3 percentage points year-on-year [38] Business Line Data and Key Metrics Changes - Value-added services (VAS) revenue was CNY 90 billion, up 14% year-on-year, with social network revenue growing 3% to CNY 31 billion [27] - Domestic games revenue increased by 15% year-on-year, driven by titles like Delta Force and Valorant [28] - International games revenue surged by 32% year-on-year, primarily from Supercell's titles and PUBG Mobile [28] - Marketing services revenue rose 17% year-on-year to CNY 41 billion, benefiting from improved ad targeting and AI enhancements [31] - Fintech and business services revenue was CNY 61 billion, up 8% year-on-year, with fintech services growing modestly [33] Market Data and Key Metrics Changes - International games business surpassed $10 billion in annual revenue for the first time, driven by evergreen and content-driven games [5] - Video Accounts became the second-largest short video service by daily active users (DAU) in China, with total time spent increasing over 20% [16] - The cloud services revenue accelerated due to increased demand and a better pricing environment amid tight supply of memory and CPU [34] Company Strategy and Development Direction - The company aims to leverage AI as a transformational force across its existing businesses, enhancing user engagement and operational efficiency [8] - Investments in AI are prioritized to strengthen core businesses before expanding into new AI products [13] - The company plans to double investments in AI products in 2026, funded by increasing earnings from core businesses [23] - The strategy includes enhancing communication services, gaming, fintech, and cloud services through AI integration [12][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of existing businesses amid AI advancements, highlighting strong user engagement and revenue trends [13] - The company anticipates that revenue growth may outpace profit growth in 2026 due to increased investments in AI [47] - Management emphasized the importance of building a strong AI talent team and securing GPU resources to support AI initiatives [50] Other Important Information - The company repurchased 153 million shares in 2025, with a total consideration of HKD 80 billion [41] - An annual dividend of HKD 5.3 per share is proposed, reflecting an 18% year-on-year increase [43] Q&A Session Questions and Answers Question: AI investment versus margin outlook - Management acknowledged that revenue may grow faster than profit in 2026 due to increased AI investments, which are seen as opportunities for expanding user value [47][48] Question: Resource allocation for AI development - Management confirmed that they have built a strong AI talent team and are actively securing GPU resources to prioritize AI product development [50][51] Question: ROI assessment for AI investments - Management indicated that they have already seen good ROI from AI applications in existing businesses and expect new AI products to generate revenue over time [54][57] Question: Differentiation in AI stack components - Management stated that they aim to invest in all layers of the AI stack, leveraging their strengths in product capability and ecosystem [60][70]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 reached CNY 1.18 billion, reflecting a year-over-year increase of 32.2% [4] - Net income was CNY 337.4 million, up 15.4% year-over-year, with a net margin of 28.7% [4] - For the full year, total revenues reached CNY 4.37 billion, representing a year-over-year increase of 33.1% [5] - Net income for the full year was CNY 1.31 billion, up 51% year-over-year, with a net margin of 29.9% [5][24] Business Line Data and Key Metrics Changes - Revenues from insurance distribution services reached CNY 4.4 billion, a 35.1% year-over-year increase [21] - Revenues from system services totaled CNY 774.1 million, up 31.1% year-over-year [22] - New policies increased by 34.5% year-over-year to approximately 7.9 million in Q4 [6] Market Data and Key Metrics Changes - The commercial health insurance industry is entering a new phase of high-quality development, supported by government policies [9] - The government work report emphasizes the importance of improving the multi-tiered healthcare security system and accelerating the development of commercial health insurance [9] Company Strategy and Development Direction - The company aims to leverage technology to promote inclusive insurance and deepen the integration of AI in its operations [18] - The focus is on enhancing operational efficiency and maintaining a strong liquidity position to support long-term growth [26] - The company is committed to expanding its insurance product matrix and improving accessibility and affordability for users [15][17] Management Comments on Operating Environment and Future Outlook - Management expects to maintain revenue and net profit growth momentum in 2026 despite intensifying industry competition [31] - The company is well-positioned to convert supportive health insurance policies into long-term business growth [46] - AI is reshaping the service models and operational efficiency of the insurance industry, providing a competitive edge [10][19] Other Important Information - The company held CNY 4.04 billion in cash reserves at the end of 2025, providing a solid financial foundation for continued investments [5] - The AI team accounted for over 10% of the total workforce, indicating a strong focus on technological capabilities [6] Q&A Session Summary Question: Guidance on top line and bottom line growth for 2026 - The company did not provide specific earnings guidance for 2026 but expects to maintain growth momentum [31] Question: Dividend plans for the coming year - The company is evaluating strategies to maximize shareholder returns, including potential dividend policies, but did not provide a specific timeline [34] Question: Outlook on sales and marketing costs for 2026 - The company expects customer demand to remain healthy and aims to maintain sales and marketing expenses as a percentage of revenue broadly stable [38] Question: Contribution breakdown between new and existing users - The majority of current users are new users, and the company’s retention strategy focuses on product innovation, user education, and industry trends [41] Question: Future drivers from policy perspective - The company sees significant catalysts from government policies aimed at expanding commercial health insurance and supporting vulnerable groups [46] Question: Development of AI agents and their impact - AI agents are seen as promising, but the company emphasizes the importance of specific usage scenarios and the distinction between different consumer engagement environments [50] Question: Impact of AI application iterations on business - The company believes AI will evolve into a full-cycle intelligent service ecosystem, enhancing its competitive edge [54]

Financial Data and Key Metrics Changes - In Q4 2025, Macy's, Inc. reported net sales of $7.6 billion, exceeding guidance of $7.35-$7.5 billion, but down from $7.8 billion last year [22][23] - Comparable sales rose 1.8%, significantly above guidance of down 2.5% to flat, with go-forward business comparable sales growth of 2% [23] - Adjusted diluted EPS was $1.67, exceeding the guidance range of $1.35-$1.55, impacted by approximately $0.13 from tariffs and $0.04 from lower asset sale gains [26] Business Line Data and Key Metrics Changes - Macy's nameplate achieved 0.6% go-forward comparable sales growth, a 190 basis points improvement year-over-year [9] - Bloomingdale's saw a remarkable 9.9% comparable sales growth, marking its best holiday result on record [23][12] - Bluemercury's comparable sales increased by 1.6%, driven by strong performance in dermatological skincare and fragrances [14] Market Data and Key Metrics Changes - Macy's digital channel accounted for approximately one-third of annual sales, benefiting from a modernized online presence [10] - The company reported a healthy credit portfolio, with credit card revenue up 17.1% year-over-year [24] - The overall market environment remains uncertain, with macroeconomic and geopolitical factors influencing consumer spending [19] Company Strategy and Development Direction - The "Bold New Chapter" strategy focuses on sustainable profitable growth, with significant progress made in 2025 [5][39] - The company plans to expand its Reimagine program to 200 locations, which will account for 60% of the go-forward Macy's store base [16] - Investments in luxury and premium brands are emphasized, with Bloomingdale's strategy centered on being a local leader in its markets [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to build on recent momentum despite external uncertainties [42] - The focus remains on customer engagement and improving Net Promoter Scores, which are at record levels [43] - The company is taking a prudent approach to guidance, reflecting both confidence in its strategy and caution regarding the macro environment [19] Other Important Information - The company returned $448 million to shareholders in 2025, including $197 million in cash dividends and $251 million in share repurchases [29][30] - Capital expenditures for 2025 were $740 million, down from $882 million in 2024, reflecting the completion of several long-term projects [28] - The company expects to close approximately 65 non-go-forward stores by 2028, allowing for optimal timing to maximize asset value [72] Q&A Session Summary Question: How does Macy's plan to remain resilient amidst consumer volatility? - Management feels confident about the growth across all nameplates and the performance of reimagined stores, emphasizing a healthy balance sheet and inventory levels [42][43] Question: Can you elaborate on Bloomingdale's recent performance? - Bloomingdale's has seen broad-based growth across various categories, with strong vendor support and continued investment in its growth potential [51][52] Question: What actions are being taken to appeal to price-sensitive consumers? - The company maintains a balance between promotional offerings and premium brands, ensuring a diverse range of price points to capture different consumer segments [59][60] Question: What are the expectations for gross margin improvement? - Management expects gross margin to improve throughout the year, driven by better assortments and enhanced customer experiences [62][63] Question: What are the plans for the Reimagine program and store closures? - The Reimagine program is expanding, with local leaders empowered to customize strategies, while store closures are being strategically timed to maximize value [70][72]

Financial Data and Key Metrics Changes - In Q4 2025, the company generated total revenue of RMB 2.08 billion, up 14% year-on-year [4] - For the full year 2025, total revenue reached RMB 8.27 billion, an increase of 12.4% year-on-year [5] - Adjusted operating profit for Q4 was RMB 900 million, up 37% year-on-year, while for the full year it was RMB 3.38 billion, up 45.7% year-on-year [6][30] - Net income for Q4 was RMB 682 million, and for the full year, it reached RMB 2.7 billion [36] - Adjusted net income increased by 25% year-on-year to RMB 906 million in Q4 and by 33% to RMB 3.6 billion for the full year [37] Business Line Data and Key Metrics Changes - The number of paid enterprise customers reached 6.83 million, up 11.6% year-on-year [11] - Revenue from small-sized accounts grew 21% year-on-year, outpacing mid-sized and key accounts [31] - The average revenue per paying user (ARPPU) remained broadly stable, reflecting increased revenue contribution from SMEs [11] Market Data and Key Metrics Changes - The average monthly active users (MAU) of the BOSS Zhipin app reached over 60.7 million, a year-on-year increase of 14.5% [7] - The platform facilitated over 2.27 billion instances of mutual consent exchanges, representing a year-on-year growth of 22.4% [8] - Revenue contribution from third-tier and lower-tier cities approached 25%, doubling compared to four years ago [10] Company Strategy and Development Direction - The company is focusing on enhancing AI capabilities to deliver closed-loop services, aiming to improve matching efficiency for job seekers and enterprises [18][19] - A commitment to shareholder returns was reinforced, with plans to allocate no less than 50% of adjusted net income for dividends and share repurchases over the next three years [28] - The company is actively penetrating the blue-collar sector and lower-tier cities, with significant growth in these areas [9] Management's Comments on Operating Environment and Future Outlook - Management noted robust growth momentum in both supply and demand during the spring recruitment season, with a healthy job seeker to enterprise user ratio [12][16] - The company expects total revenues for Q1 2026 to be between RMB 2.050 billion and RMB 2.085 billion, reflecting a year-on-year increase of 6.6% to 8.4% [39] - Management expressed confidence in the long-term growth potential despite challenges posed by AI technology [41][49] Other Important Information - The company declared a dividend of $80 million for 2025 and has already repurchased $50 million worth of shares in 2026 [38] - The cash position stood at RMB 19.9 billion as of December 31, 2025, which will be leveraged for future growth initiatives [37] Q&A Session Summary Question: Concerns about AI's impact on white-collar jobs - Management acknowledged the debate around AI potentially reducing demand for white-collar hiring but emphasized that AI can enhance labor efficiency and create new job opportunities [41][44] Question: Plans for AI product testing and monetization - Management expects significant revenue growth from closed-loop placement services, anticipating that revenue could double or triple this year [63] Question: User growth target for 2026 and margin trends - The company aims to add at least 40 million newly verified users in 2026 and expects overall adjusted operating profit margins to slightly increase [74]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was RMB 194.4 billion, up 13% year-on-year [34] - Gross profit increased to RMB 108.3 billion, reflecting a 19% year-on-year growth [34] - Non-IFRS operating profit was RMB 69.5 billion, up 17% year-on-year [36] - Non-IFRS net profit attributable to equity holders was RMB 64.7 billion, also up 17% year-on-year [36] - Overall gross margin improved to 56%, up 3 percentage points year-on-year [37] Business Line Data and Key Metrics Changes - Value-added services (VAS) revenue was RMB 90 billion, up 14% year-on-year, with social network revenue growing 3% to RMB 31 billion [25] - Domestic games revenue increased by 15% year-on-year, driven by titles like Delta Force and Valorant [26] - International games revenue surged by 32% year-on-year, primarily from Supercell's titles and PUBG Mobile [26] - Marketing services revenue rose 17% year-on-year to RMB 41 billion, benefiting from improved ad targeting and AI enhancements [30] - Fintech and business services revenue was RMB 61 billion, up 8%, with fintech services growing by a single-digit percentage [31] Market Data and Key Metrics Changes - Video Accounts total time spent increased over 20% due to upgraded recommendation algorithms [3] - The international games business surpassed $10 billion in annual revenue for the first time [4] - Tencent Cloud achieved RMB 5 billion adjusted operating profit, reflecting improved earnings despite revenue headwinds [23] Company Strategy and Development Direction - The company aims to leverage AI as a transformational force across its core businesses, enhancing user engagement and operational efficiency [6][11] - Investments in AI products are expected to double in 2026, funded by increasing earnings from core businesses [20] - The strategy includes strengthening existing businesses with AI before expanding into new AI products [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that revenue growth may outpace profit growth in 2026 due to increased investments in AI [46] - The company is actively recruiting top AI talent and increasing compute resources to address GPU constraints [49] - Management believes that AI will provide significant long-term returns, similar to the trajectory of Tencent Cloud [58] Other Important Information - The company plans to propose an annual dividend of HKD 5.3 per share, reflecting an 18% year-on-year increase [41] - Free cash flow for Q4 2025 was RMB 34 billion, increasing over six times year-on-year [39] Q&A Session Questions and Answers Question: How should we think about profit margins in relation to AI investments? - Management indicated that revenue could grow faster than profit in 2026 due to increased AI investments, which are seen as opportunities for expanding user value [46] Question: How is the company prioritizing resources in light of GPU and AI talent constraints? - Management stated that they have built a strong AI talent team and are actively provisioning more compute resources, focusing on HunYuan and new AI products [49][50] Question: What is the assessment of ROI for AI investments? - Management noted that they have already seen good ROIs from AI applications in existing businesses and expect new AI products to generate attractive returns over time [58]

Financial Data and Key Metrics Changes - In 2025, XOMA Royalty reported total GAAP income and revenue of $52.1 million, a significant increase from $28.5 million in 2024 [22] - Total cash receipts grew by 9% to $50.5 million, with royalty receipts reaching approximately $34 million, marking a 68% increase compared to 2024 [22][24] - Full-year GAAP net income was $31.7 million, compared to a GAAP net loss of $13.8 million in 2024 [24] Business Line Data and Key Metrics Changes - The company added 22 assets to its portfolio in 2025, including 7 commercially available programs, enhancing its recurring revenue sources [4][5] - Royalty receipts came from four programs, two more than in 2024, and six programs achieved clinical, regulatory, and business development events, leading to approximately $17 million in cash milestone payments [22] Market Data and Key Metrics Changes - The portfolio's total receipts surpassed $50 million, driven by significant contributions from VABYSMO and OJEMDA, as well as new contributions from MIPLYFFA [4][22] - The company anticipates continued growth in royalty receipts from approved products, particularly from VABYSMO, OJEMDA, and MIPLYFFA [33] Company Strategy and Development Direction - XOMA Royalty aims to build a diversified portfolio of biotechnology royalty and milestone assets while maintaining disciplined capital allocation [11] - The company executed a strategic revenue share transaction with Takeda, adding potential royalty and milestone payments across nine programs [10] - The focus remains on innovative transactions and underappreciated opportunities to expand the portfolio without diluting shareholders [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for royalty receipts, particularly from VABYSMO, OJEMDA, and MIPLYFFA, which are expected to ramp up in the coming years [33] - The company is approaching an inflection point where royalty receipts alone could cover operating expenses by 2027 [28] - Management remains optimistic about the potential for future milestone payments and royalty growth from a robust late-stage pipeline [9][12] Other Important Information - The company maintained a strong balance sheet with approximately $83 million in unrestricted cash and cash equivalents, providing ample resources for future investments [27] - XOMA Royalty has successfully avoided shareholder dilution, with a share count remaining flat compared to 2023 [13] Q&A Session Summary Question: Growth prospects for royalty receipts on approved products - Management indicated strong growth prospects, particularly from VABYSMO, which had double-digit growth last year, and positive expectations for OJEMDA and MIPLYFFA [33] Question: Details on the Tremfya economic opportunity - Management expressed confidence in the breach claim related to Tremfya, citing historical relationships and potential royalty rates in the low single digits [34][35] Question: Capital deployment strategy - Management emphasized a balance between returning capital to shareholders and investing in new deals, favoring internal investments that enhance cash flow per share [46][48] Question: Opportunity size for Rezolute's program for ersodetug - Management estimated the combined opportunity for the two indications at approximately $1 billion, with a favorable split between congenital and tumor hyperinsulinism [50][52] Question: Evolution of the royalty model and deal activity - Management stated a preference for quality over quantity in deal-making, focusing on driving risk-adjusted net present value rather than setting specific targets for deal volume [58][60] Question: Amendment of the Takeda deal - Management explained that the amendment was driven by initial discussions with BioInvent and the desire to diversify revenue streams through collaboration with Takeda [68][74] Question: Future capital structure changes - Management indicated that the current capital structure is effective, but they may explore optimizing it over the next 12 months, particularly regarding preferred equity [76][77]

Financial Data and Key Metrics Changes - For Q4 2025, total group revenue was RMB 2.58 billion, down 2% year-over-year, with domestic revenue at RMB 1.97 billion, down 14% year-over-year, and overseas revenue at RMB 608 million, up 70% year-over-year [5][20] - For fiscal 2025, total group revenue was RMB 10.37 billion, a slight decrease of less than 2% year-over-year, with domestic revenue at RMB 8.37 billion, down 11% year-over-year, and overseas revenue at RMB 2 billion, up 71% year-over-year [6][19] Business Line Data and Key Metrics Changes - Momo's live revenue in Q4 was RMB 1.68 billion, a year-over-year decrease of 14% and a sequential decrease of 6% [10] - Tantan's domestic revenue in Q4 was RMB 136 million, down RMB 41 million year-over-year and RMB 16 million quarter-over-quarter [12] - Momo had 3.9 million paying users in Q4, an increase of 200,000 quarter-over-quarter, indicating a recovery in user engagement [9] Market Data and Key Metrics Changes - Overseas revenue accounted for 24% of total revenue in Q4, up from 14% in the same period last year, indicating a significant shift towards international markets [5] - The overseas business is now a solidified revenue contributor and a key engine for future growth, driven by successful product launches in the MENA region [4][15] Company Strategy and Development Direction - The company is focusing on maintaining productivity in Momo, enhancing the dating experience in Tantan, and expanding new businesses for growth [18] - Strategic priorities for 2026 include strengthening regional operations, particularly in MENA, and leveraging acquisitions to penetrate new markets [17][18] Management Comments on Operating Environment and Future Outlook - Management noted that the domestic business faced challenges in 2025 due to new tax regulations and macroeconomic pressures, but they are optimistic about stabilizing revenue in the second half of 2026 [34][39] - The company expects continued revenue pressures in 2026, with a projected decline in domestic revenue and growth in overseas revenue [35][38] Other Important Information - A special cash dividend of $0.28 per ADS was approved, totaling approximately $42.6 million, reflecting the company's commitment to shareholder value [19] - The company ended Q4 2025 with cash reserves of RMB 8.68 billion, down from RMB 14.73 billion a year earlier, due to various financial activities including dividend payments and acquisitions [27] Q&A Session Summary Question: Domestic revenue trend and measures to stabilize it - Management acknowledged the challenges faced in 2025 but highlighted successful strategies to attract mid-tier users and maintain profitability despite revenue declines [33][34] Question: Revenue contribution from overseas business and growth trends - Management indicated that overseas revenue is expected to grow significantly, driven by new products in the MENA region, with a target of RMB 3 billion in overseas revenue for 2026 [45][51] Question: Gross margin stability and overall revenue guidance for 2026 - Management confirmed that Q4 gross margin was stable and could remain at similar levels in 2026, with overall revenue expected to be flat due to domestic declines and overseas growth [62][64]